AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9385624 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 mg of immediate-release PPA (administered orally via a gelatin capsule)
Number of subjects: 20
Study 9385624 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 7611920 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol (25 mg/day for 8 weeks)
Number of subjects: 106
Study 7611920 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine (40 mg/day b.i.d. for 8 weeks)
Number of subjects: 106
Study 7611920 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 106
Study 7611920 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine
Number of subjects: 106
Study 3494711 — intervention group
Group type: EXPERIMENTAL
Intervention: Inpatient teaching programs
Number of subjects: 0
Study 29112242 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone (MP+)
Number of subjects: 108
Study 29112242 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporine and methotrexate with methylprednisolone (MP+)
Number of subjects: 108
Study 29112242 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporine and methotrexate without methylprednisolone (MP-)
Number of subjects: 108
Study 28318161 — intervention group
Group type: EXPERIMENTAL
Intervention: Periodontal therapy and root-canal treatment (experimental group)
Number of subjects: 180
Study 28318161 — intervention group
Group type: COMPARATOR
Intervention: Periodontal treatment alone (control group)
Number of subjects: 180
Study 24005884 — intervention group
Group type: COMPARATOR
Intervention: Port devices
Number of subjects: 70
Study 24005884 — intervention group
Group type: EXPERIMENTAL
Intervention: PICC lines
Number of subjects: 70
Study 22381566 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D computerised planning
Number of subjects: 60
Study 22381566 — intervention group
Group type: COMPARATOR
Intervention: 2D templating
Number of subjects: 60
Study 16450574 — intervention group
Group type: EXPERIMENTAL
Intervention: Desloratadine/pseudoephedrine, 2.5/120 mg b.i.d.
Number of subjects: 650
Study 16450574 — intervention group
Group type: COMPARATOR
Intervention: Desloratadine, 5 mg once per day
Number of subjects: 650
Study 16450574 — intervention group
Group type: COMPARATOR
Intervention: Pseudoephedrine, 120 mg b.i.d.
Number of subjects: 650
Study 12378662 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 2 mg ml‐1
Number of subjects: 64
Study 12378662 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 5 mg ml‐1
Number of subjects: 64
Study 12378662 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 7.5 mg ml‐1
Number of subjects: 64
Study 12378662 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 10 mg ml‐1
Number of subjects: 64
Study 12378662 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0% Ropivacaine
Number of subjects: 64
Study 9924905 — intervention group
Group type: EXPERIMENTAL
Intervention: Vigabatrin (VGB) 1 g/day
Number of subjects: 174
Study 9924905 — intervention group
Group type: EXPERIMENTAL
Intervention: Vigabatrin (VGB) 3 g/day
Number of subjects: 174
Study 9924905 — intervention group
Group type: EXPERIMENTAL
Intervention: Vigabatrin (VGB) 6 g/day
Number of subjects: 174
Study 9924905 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 174
Study 8849986 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane 2% administered before sternotomy for ten minutes
Number of subjects: 30
Study 8849986 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane 2% administered after sternotomy for ten minutes
Number of subjects: 30
Study 2153777 — intervention group
Group type: EXPERIMENTAL
Intervention: Programmed Unit of Instruction (PUI) for infection control
Number of subjects: 108
Study 2153777 — intervention group
Group type: COMPARATOR
Intervention: Lecture format for infection control (Control)
Number of subjects: 108
Study 7367947 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemodialysis
Number of subjects: 1
Study 7367947 — intervention group
Group type: COMPARATOR
Intervention: Sham dialysis
Number of subjects: 1
Study 29554379 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Surgical Training System (VSTS) - Simulation Training (ST) group
Number of subjects: 10
Study 29554379 — intervention group
Group type: COMPARATOR
Intervention: Introductory teaching session - Control group
Number of subjects: 10
Study 28608719 — intervention group
Group type: EXPERIMENTAL
Intervention: Home monitoring intervention with spirometry and symptom monitoring twice per week.
Number of subjects: 267
Study 28608719 — intervention group
Group type: COMPARATOR
Intervention: Usual care arm (seen every 3 months, contact if worsening symptoms).
Number of subjects: 267
Study 24973731 — intervention group
Group type: EXPERIMENTAL
Intervention: Functionally orientated treatment (SDA)
Number of subjects: 89
Study 24973731 — intervention group
Group type: COMPARATOR
Intervention: Removable partial dentures (RPD)
Number of subjects: 89
Study 23827658 — intervention group
Group type: EXPERIMENTAL
Intervention: Training, support, and activity therapy intervention
Number of subjects: 304
Study 23827658 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 304
Study 21192270 — intervention group
Group type: EXPERIMENTAL
Intervention: CobraPLUS
Number of subjects: 180
Study 21192270 — intervention group
Group type: EXPERIMENTAL
Intervention: Cookgas air-Q
Number of subjects: 180
Study 21192270 — intervention group
Group type: COMPARATOR
Intervention: Fastrach ILMA
Number of subjects: 180
Study 21192270 — intervention group
Group type: EXPERIMENTAL
Intervention: CobraPLUS, Cookgas air-Q, Fastrach ILMA
Number of subjects: 180
Study 18490886 — intervention group
Group type: EXPERIMENTAL
Intervention: Foot reflexotherapy (20 minutes during postoperative days 2, 3, and 4)
Number of subjects: 61
Study 18490886 — intervention group
Group type: COMPARATOR
Intervention: Usual pain management
Number of subjects: 61
Study 17062449 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term multi-session intervention
Number of subjects: 54
Study 17062449 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term single session intervention
Number of subjects: 54
Study 17062449 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 54
Study 12921496 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone sodium succinate 50 mg intravenous piggyback (IVPB) prior to infusion and repeated 1 hour into the infusion
Number of subjects: 143
Study 12921496 — intervention group
Group type: COMPARATOR
Intervention: Standard regimen of acetaminophen 650 mg orally with diphenhydramine 50 mg intravenously
Number of subjects: 143
Study 10872150 — intervention group
Group type: EXPERIMENTAL
Intervention: MR angiography (MRA)
Number of subjects: 34
Study 10872150 — intervention group
Group type: COMPARATOR
Intervention: Digital subtraction angiography (DSA)
Number of subjects: 34
Study 10872150 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined readings of MRA and DSA
Number of subjects: 34
Study 10872150 — intervention group
Group type: EXPERIMENTAL
Intervention: Interobserver agreement
Number of subjects: 34
Study 10872150 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermethod agreement
Number of subjects: 34
Study 10872150 — intervention group
Group type: EXPERIMENTAL
Intervention: MRA and DSA
Number of subjects: 34
Study 9477787 — intervention group
Group type: EXPERIMENTAL
Intervention: Autogeneic, allogeneic, and alloplastic sinus grafts (individually or mixed)
Number of subjects: 27
Study 9477787 — intervention group
Group type: EXPERIMENTAL
Intervention: Root form implants placed in augmented sinuses
Number of subjects: 27
Study 9477787 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean Periotest value at uncovering
Number of subjects: 27
Study 1587197 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil (240 mg/day)
Number of subjects: 15
Study 1587197 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 3544625 — intervention group
Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (KABI 2165) 5,000 U once daily
Number of subjects: 52
Study 3544625 — intervention group
Group type: COMPARATOR
Intervention: Conventional heparin 5,000 IU twice daily
Number of subjects: 52
Study 30961460 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 (2 g) plus Vitamin E (400 IU)
Number of subjects: 62
Study 30961460 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study 28408067 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyphenol supplementation
Number of subjects: 28
Study 28408067 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Control)
Number of subjects: 28
Study 26819200 — intervention group
Group type: COMPARATOR
Intervention: Total 100 % energy restriction (ER)
Number of subjects: 10
Study 26819200 — intervention group
Group type: COMPARATOR
Intervention: Partial 75 % energy restriction (ER)
Number of subjects: 10
Study 26819200 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoenergetic intake
Number of subjects: 10
Study 23937144 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity resistance exercise (80% of 1RM)
Number of subjects: 10
Study 23937144 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-intensity resistance exercise (50% of 1RM)
Number of subjects: 10
Study 23937144 — intervention group
Group type: COMPARATOR
Intervention: Control session (rest)
Number of subjects: 10
Study 22788842 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporine A (N = 36)
Number of subjects: 70
Study 22788842 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus (N = 34)
Number of subjects: 70
Study 22788842 — intervention group
Group type: COMPARATOR
Intervention: Both Cyclosporine A and Tacrolimus
Number of subjects: 70
Study 20427683 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen therapy (HBOT)
Number of subjects: 94
Study 20427683 — intervention group
Group type: COMPARATOR
Intervention: Hyperbaric air (placebo)
Number of subjects: 94
Study 18176223 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone morphogenetic protein-2 (BMP-2)
Number of subjects: 21
Study 18176223 — intervention group
Group type: COMPARATOR
Intervention: Traditional iliac crest bone graft
Number of subjects: 21
Study 15923414 — intervention group
Group type: EXPERIMENTAL
Intervention: Home Treatment (HT) with low molecular weight heparin (LMWH) followed by warfarin
Number of subjects: 207
Study 15923414 — intervention group
Group type: EXPERIMENTAL
Intervention: Home Treatment (HT) with low molecular weight heparin (LMWH) alone
Number of subjects: 207
Study 15923414 — intervention group
Group type: COMPARATOR
Intervention: Hospitalized treatment with LMWH and warfarin
Number of subjects: 207
Study 15923414 — intervention group
Group type: COMPARATOR
Intervention: Hospitalized treatment with LMWH alone
Number of subjects: 207
Study 15923414 — intervention group
Group type: EXPERIMENTAL
Intervention: Home Treatment (HT)
Number of subjects: 207
Study 15923414 — intervention group
Group type: COMPARATOR
Intervention: Hospitalized treatment
Number of subjects: 207
Study 12607659 — intervention group
Group type: EXPERIMENTAL
Intervention: etodolac
Number of subjects: 60
Study 12607659 — intervention group
Group type: EXPERIMENTAL
Intervention: diclofenac
Number of subjects: 60
Study 12607659 — intervention group
Group type: COMPARATOR
Intervention: tramadol
Number of subjects: 60
Study 10232435 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombolytic therapy
Number of subjects: 23
Study 8909629 — intervention group
Group type: EXPERIMENTAL
Intervention: PeaceBuilders intervention implemented in four schools starting in Year 1
Number of subjects: 2736
Study 8909629 — intervention group
Group type: COMPARATOR
Intervention: Control group (four schools starting PeaceBuilders in Year 2)
Number of subjects: 2736
Study 1882906 — intervention group
Group type: EXPERIMENTAL
Intervention: sucralfate, 1 g q.i.d., 0.5 hour before meals on an empty stomach or at bedtime
Number of subjects: 90
Study 1882906 — intervention group
Group type: COMPARATOR
Intervention: ranitidine, 150 mg b.i.d.
Number of subjects: 90
Study 1882906 — intervention group
Group type: EXPERIMENTAL
Intervention: sucralfate, 1 g b.i.d. (before breakfast and at bedtime)
Number of subjects: 90
Study 1882906 — intervention group
Group type: COMPARATOR
Intervention: ranitidine, 150 mg at bedtime
Number of subjects: 90
Study 1882906 — intervention group
Group type: EXPERIMENTAL
Intervention: sucralfate
Number of subjects: 90
Study 1882906 — intervention group
Group type: COMPARATOR
Intervention: ranitidine
Number of subjects: 90
Study 7057465 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplemental albumin therapy
Number of subjects: 184
Study 7057465 — intervention group
Group type: COMPARATOR
Intervention: Control patients
Number of subjects: 184
Study 7057465 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplemental steroid therapy
Number of subjects: 184
Study 31085528 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent-targeted online intervention combining microbiological local syndromic surveillance data, symptom information, and home-care advice
Number of subjects: 806
Study 31085528 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent-targeted online intervention
Number of subjects: 806
Study 31085528 — intervention group
Group type: COMPARATOR
Intervention: Control group (received material after answering questions)
Number of subjects: 806
Study 28674829 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 Hz-matrix stimulation (EC2) with 5 min duration and 1200 stimuli
Number of subjects: 30
Study 28674829 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 Hz-matrix stimulation (EC1) with 2.5 min duration and 600 stimuli
Number of subjects: 30
Study 28674829 — intervention group
Group type: COMPARATOR
Intervention: Control group (no stimulation)
Number of subjects: 30
Study 26369473 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery (gastric bypass)
Number of subjects: 60
Study 26369473 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery (biliopancreatic diversion)
Number of subjects: 60
Study 26369473 — intervention group
Group type: COMPARATOR
Intervention: Medical treatment
Number of subjects: 60
Study 24388622 — intervention group
Group type: EXPERIMENTAL
Intervention: ezetimibe + fluvastatin (10 mg/day + 30 mg/day)
Number of subjects: 63
Study 24388622 — intervention group
Group type: COMPARATOR
Intervention: fluvastatin alone (30 mg/day)
Number of subjects: 63
Study 22107110 — intervention group
Group type: EXPERIMENTAL
Intervention: Text message programme targeted at changing illness and medication beliefs over 18 weeks
Number of subjects: 216
Study 22107110 — intervention group
Group type: EXPERIMENTAL
Intervention: Text message programme
Number of subjects: 216
Study 22107110 — intervention group
Group type: COMPARATOR
Intervention: Control group (no text messages)
Number of subjects: 216
Study 22107110 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (text message programme)
Number of subjects: 216
Study 19243710 — intervention group
Group type: EXPERIMENTAL
Intervention: Olopatadine hydrochloride nasal spray 0.6% (OLO)
Number of subjects: 544
Study 19243710 — intervention group
Group type: COMPARATOR
Intervention: Azelastine hydrochloride nasal spray 0.1% (AZE)
Number of subjects: 544
Study 19243710 — intervention group
Group type: COMPARATOR
Intervention: Inactive vehicle (placebo control)
Number of subjects: 544
Study 18163018 — intervention group
Group type: EXPERIMENTAL
Intervention: Colchicine (1.0 mg twice daily for the first day followed by 0.5 mg twice daily for 1 month for patients ≥70 kg; halved doses for patients <70 kg or intolerant)
Number of subjects: 360
Study 18163018 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 360
Study 18163018 — intervention group
Group type: EXPERIMENTAL
Intervention: Colchicine
Number of subjects: 360
Study 15195238 — intervention group
Group type: EXPERIMENTAL
Intervention: Trivalent inactivated influenza virus vaccine (TVV) + Trivalent live cold‐adapted influenza virus vaccine (CAIV-T)
Number of subjects: 2215
Study 15195238 — intervention group
Group type: COMPARATOR
Intervention: Trivalent inactivated influenza virus vaccine (TVV) + Placebo (P)
Number of subjects: 2215
Study 11375845 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous thoracic epidural anesthesia (TEA) with 0.2% ropivacaine
Number of subjects: 60
Study 11375845 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia (GA)
Number of subjects: 60
Study 9790376 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 2503
Study 9790376 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2503
Study 7659479 — intervention group
Group type: EXPERIMENTAL
Intervention: HbOC (Haemophilus b oligosaccharide conjugate vaccine) administered simultaneously with DTaP or DTP
Number of subjects: 0
Study 7659479 — intervention group
Group type: COMPARATOR
Intervention: DTaP vaccines
Number of subjects: 0
Study 7659479 — intervention group
Group type: COMPARATOR
Intervention: DTP vaccines
Number of subjects: 0
Study 2697585 — intervention group
Group type: EXPERIMENTAL
Intervention: MP/IFN
Number of subjects: 158
Study 2697585 — intervention group
Group type: COMPARATOR
Intervention: MP
Number of subjects: 158
Study 1094544 — intervention group
Group type: EXPERIMENTAL
Intervention: Thioridazine
Number of subjects: 40
Study 1094544 — intervention group
Group type: COMPARATOR
Intervention: Diazepam
Number of subjects: 40
Study 30092827 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab (IFX) + Methotrexate (MTX)
Number of subjects: 90
Study 30092827 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate (MTX) alone
Number of subjects: 90
Study 30092827 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 90
Study 27804264 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight Watchers program (WW) with telephone and email consultations from a certified diabetes educator
Number of subjects: 563
Study 27804264 — intervention group
Group type: COMPARATOR
Intervention: Standard care (SC)
Number of subjects: 563
Study 23992556 — intervention group
Group type: EXPERIMENTAL
Intervention: Broccoli consumption (250 g/day for 10 days)
Number of subjects: 100
Study 23457987 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended program of social and hygienic monitoring including risk factors for diseases based on lifestyle and periodic health examination groups.
Number of subjects: 0
Study 20230136 — intervention group
Group type: EXPERIMENTAL
Intervention: Group Reminiscence (GR)
Number of subjects: 73
Study 20230136 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual Reminiscence (IR)
Number of subjects: 73
Study 20230136 — intervention group
Group type: COMPARATOR
Intervention: Group Control Activity (C)
Number of subjects: 73
Study 18372433 — intervention group
Group type: EXPERIMENTAL
Intervention: Iloprost 50 microg twice daily
Number of subjects: 430
Study 18372433 — intervention group
Group type: EXPERIMENTAL
Intervention: Iloprost 100 microg twice daily
Number of subjects: 430
Study 18372433 — intervention group
Group type: EXPERIMENTAL
Intervention: Iloprost 150 microg twice daily
Number of subjects: 430
Study 18372433 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline
Number of subjects: 430
Study 18372433 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 430
Study 15720350 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold biopsy followed by bipolar electrocoagulation (Group A) using a 10 Fr catheter with setting 8 (40 W) for 1 second.
Number of subjects: 50
Study 15720350 — intervention group
Group type: COMPARATOR
Intervention: Conventional monopolar hot biopsy forceps (Group B).
Number of subjects: 50
Study 11333166 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-blockers
Number of subjects: 199
Study 9443519 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeinated coffee (1.5 mg/kg caffeine/body weight)
Number of subjects: 46
Study 9443519 — intervention group
Group type: EXPERIMENTAL
Intervention: Decaffeinated coffee
Number of subjects: 46
Study 9443519 — intervention group
Group type: COMPARATOR
Intervention: Fruit juice
Number of subjects: 46
Study 8197032 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticarcillin-clavulanic acid (T-C) 3.1 g
Number of subjects: 9
Study 8197032 — intervention group
Group type: EXPERIMENTAL
Intervention: Ampicillin-sulbactam (A-S) 3 g
Number of subjects: 9
Study 8197032 — intervention group
Group type: COMPARATOR
Intervention: Ticarcillin-clavulanic acid (T-C)
Number of subjects: 9
Study 8197032 — intervention group
Group type: COMPARATOR
Intervention: Ampicillin-sulbactam (A-S)
Number of subjects: 9
Study 3295035 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril (25 or 50 mg given thrice daily)
Number of subjects: 18
Study 3295035 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin (50 mg given thrice daily)
Number of subjects: 18
Study 3295035 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril plus Indomethacin
Number of subjects: 18
Study 3295035 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril alone
Number of subjects: 18
Study 3295035 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 2676528 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac
Number of subjects: 67
Study 2676528 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin
Number of subjects: 67
Study 2676528 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 67
Study 2676528 — intervention group
Group type: COMPARATOR
Intervention: Balanced anaesthesia
Number of subjects: 67
Study 31759036 — intervention group
Group type: EXPERIMENTAL
Intervention: Liquid-based cytology (LBC)
Number of subjects: 170
Study 31119481 — intervention group
Group type: EXPERIMENTAL
Intervention: Osimertinib
Number of subjects: 43
Study 28011207 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil 50 mg
Number of subjects: 278
Study 28011207 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil 100 mg
Number of subjects: 278
Study 28011207 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 278
Study 25133822 — intervention group
Group type: COMPARATOR
Intervention: Standard invitation letter
Number of subjects: 1000
Study 25133822 — intervention group
Group type: EXPERIMENTAL
Intervention: Invitation letter with vouchers worth 45 for undergoing 3 vaccinations
Number of subjects: 1000
Study 23240706 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressant medication
Number of subjects: 29
Study 23240706 — intervention group
Group type: COMPARATOR
Intervention: Cognitive Behavior Therapy (CBT)
Number of subjects: 29
Study 22118479 — intervention group
Group type: EXPERIMENTAL
Intervention: Conservative treatment
Number of subjects: 291